Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and gemcitabine in ERCC1-positive advanced non-small cell lung cancer
2009-010656-10Phase 2Terminated
- Sponsor
- Fondazione Salvatore Maugeri
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Fondazione Salvatore Maugeri. Primary endpoint: Objective response rate. Started Mar 2009; status: terminated.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-010656-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010656-10.